Avaliação econômica no âmbito das doenças raras: Isto é possível?

16Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This study analyzes the available evidence on the adequacy of economic evaluation for decision- making on the incorporation or exclusion of technologies for rare diseases. The authors conducted a structured literature review in MEDLINE via PubMed, CRD, LILACS, SciELO, and Google Scholar (gray literature). Economic evaluation studies had their origins in Welfare Economics, in which individuals maximize their utilities based on allocative efficiency. There is no widely accepted criterion in the literature to weigh the expected utilities, in the sense of assigning more weight to individuals with greater health needs. Thus, economic evaluation studies do not usually weigh utilities asymmetrically (that is, everyone is treated equally, which in Brazil is also a Constitutional principle). Healthcare systems have ratified the use of economic evaluation as the main tool to assist decision-making. However, this approach does not rule out the use of other methodologies to complement costeffectiveness studies, such as Person Trade-Off and Rule of Rescue.

Cite

CITATION STYLE

APA

da Silva, E. N., & Sousa, T. R. V. (2015). Avaliação econômica no âmbito das doenças raras: Isto é possível? Cadernos de Saude Publica, 31(3), 496–506. https://doi.org/10.1590/0102-311X00213813

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free